C2 CryoBalloon™ 180 Ablation System Dose De-escalation Study.
← catalyst calendarSponsored by Merit Medical Systems, Inc. (industry) · MMSI — their whole pipeline →.
Phase
Not applicable
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
62actual
Sites
6
Country
Netherlands
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-01-16 | actual | When the study began enrolling |
| Primary completion | 2026-06-18 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-18 | estimated | The whole study's end, after follow-up |
| First posted | 2017-10-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Barrett Esophagus
Intervention
- Device: C2 CryoBalloon 180° Ablation System — also filed as CryoBalloon 180
Primary outcomes
what the primary-completion date above is the date OFEfficacy: Dose response
measured 10 weeks
Safety: Incidence of Dose-related SAEs
measured 30 days
Permalink · MMSI's whole pipeline · Catalyst calendar · Every registered study · What changed